Perhaps the UCLA combo trial's 6 months PFS results and our P3 results should closely follow one another. Good results released at the same time from both trial would greatly magnify the efficacy of DCVax-L as well as keytruda. Releasing positive DCVax-L and positive UCLA combo trial results at different times would of course still be a plus but would not in my opinion elicit the powerful attention that a simultaneous release of results would produce.
OTOH if the UCLA trial is a failure in that autologous dendritic cell vaccines alone or in combination with keytruda fail to significantly delay progression, the UCLA combo trial results should be released after release of the DCVax-L trial results. Negative UCLA combo trial results released before the release of DCVax-L trial results, would not only lower the SP before TLD/publication but would blunt even very positive DCVax-L trial results. That would be true even if the UCLA autologous dendritic cell vaccine demonstrated efficacy and the failure was totally due to keytruda
because the naysayers and shorts would find a way to trash both ingredients.
I trust that Linda Liau will know when the DCVax-L TLD/publication will appear and depending on the UCLA combo trial results, can therefore choose with her UCLA-Merck partners, the time for the release of the UCLA combo trial results.
Market Data 
Markets 
AI
